PitchSend

Allurion SPAC Presentation Deck

A GLP-1 Drugs Face Several Challenges Allurion Can Capitalize Upon Poor Experience Weekly injection Real-world drop- out rates of 45-65%¹ Loss of muscle mass³ 19.9 High Risks Thyroid cancer associated with long-term use² 9.8% serious adverse event rate³ High Costs $1,000 per month with limited insurance coverage4 000 Weight Re-Gain Weight is re- gained quickly if drugs are stopped5 Sources: 1) Weiss et al. BMJ Open Diab Res and Care 2022;10:e002517. 2) Bezin et al. Diabetes Care 2023;46(2):384-91. 3) Wilding et al. N Engl J Med 2021;384:989-1002, 4) GoodRx. https://www.goodrx.com/wegovy. 5) Wilding et al. Diabetes Obes Metab. 2022;24(8): 1553-64.

View entire presentation